FI3962534T3 - Proteiineja, joilla on kardioprotektiivinen vaikutus - Google Patents

Proteiineja, joilla on kardioprotektiivinen vaikutus Download PDF

Info

Publication number
FI3962534T3
FI3962534T3 FIEP20721637.5T FI20721637T FI3962534T3 FI 3962534 T3 FI3962534 T3 FI 3962534T3 FI 20721637 T FI20721637 T FI 20721637T FI 3962534 T3 FI3962534 T3 FI 3962534T3
Authority
FI
Finland
Prior art keywords
fam3c
polynucleotide
vector
use according
heart disease
Prior art date
Application number
FIEP20721637.5T
Other languages
English (en)
Finnish (fi)
Inventor
Mauro Giacca
Giulia Ruozi
Francesca Bortolotti
Original Assignee
Int Centre For Genetic Engineering And Biotechnology Icgeb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Centre For Genetic Engineering And Biotechnology Icgeb filed Critical Int Centre For Genetic Engineering And Biotechnology Icgeb
Application granted granted Critical
Publication of FI3962534T3 publication Critical patent/FI3962534T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
FIEP20721637.5T 2019-04-30 2020-04-30 Proteiineja, joilla on kardioprotektiivinen vaikutus FI3962534T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1906052.4A GB201906052D0 (en) 2019-04-30 2019-04-30 Proteins with cardioprotective activity
PCT/EP2020/062156 WO2020221906A1 (en) 2019-04-30 2020-04-30 Proteins with cardioprotective activity

Publications (1)

Publication Number Publication Date
FI3962534T3 true FI3962534T3 (fi) 2024-04-17

Family

ID=66589570

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20721637.5T FI3962534T3 (fi) 2019-04-30 2020-04-30 Proteiineja, joilla on kardioprotektiivinen vaikutus

Country Status (25)

Country Link
US (3) US12569574B2 (enExample)
EP (2) EP3962534B1 (enExample)
JP (2) JP7707075B2 (enExample)
KR (2) KR20220027829A (enExample)
CN (2) CN120518738A (enExample)
AU (1) AU2020267029A1 (enExample)
BR (1) BR112021021626A2 (enExample)
CA (1) CA3137662A1 (enExample)
DK (1) DK3962534T3 (enExample)
ES (1) ES2975422T3 (enExample)
FI (1) FI3962534T3 (enExample)
GB (1) GB201906052D0 (enExample)
HR (1) HRP20240441T1 (enExample)
HU (1) HUE066324T2 (enExample)
IL (1) IL287525A (enExample)
LT (1) LT3962534T (enExample)
MX (2) MX2021013298A (enExample)
PL (1) PL3962534T3 (enExample)
PT (1) PT3962534T (enExample)
RS (1) RS65469B1 (enExample)
SG (1) SG11202111267WA (enExample)
SI (1) SI3962534T1 (enExample)
SM (1) SMT202400151T1 (enExample)
WO (1) WO2020221906A1 (enExample)
ZA (2) ZA202107778B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity
WO2025253097A1 (en) * 2024-06-03 2025-12-11 Forcefield Therapeutics Limited Proteins with cardiopreservation activity
GB202415505D0 (en) * 2024-10-21 2024-12-04 King S College London Lipid nanoparticles for cardiac protection

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416538A1 (en) * 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003265867A1 (en) * 2002-08-29 2004-10-18 Oxford Glycosciences (Uk) Ltd. A3 receptor-mediated cardioprotective proteins and therapeutic and diagnostic methods of use
US7312079B1 (en) * 2005-10-06 2007-12-25 Lexicon Pharmaceuticals, Inc. Variants of FAM3C
DK2623605T3 (en) 2007-04-09 2019-03-25 Univ Florida RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
US20130136738A1 (en) * 2010-01-26 2013-05-30 Zhaodan Cao Methods of Treating Glucose Metabolism Disorders
EP2533796A4 (en) * 2010-02-12 2013-12-04 Ngm Biopharmaceuticals Inc METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
KR102248900B1 (ko) 2011-09-30 2021-05-07 소마로직, 인크. 심혈관 위험 사건 예측 및 그것의 용도
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
EP2981334A4 (en) * 2013-04-03 2016-11-23 Univ California COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY
US20170209621A1 (en) * 2016-01-21 2017-07-27 The Board Of Trustees Of The Leland Stanford Junior University Use of chordin-like 1 or collagen vi with mesenchymal stem cells
KR102022021B1 (ko) * 2018-01-10 2019-09-18 한국과학기술연구원 심혈관 질환의 진단을 위한 바이오마커 및 이의 용도
GB201906052D0 (en) 2019-04-30 2019-06-12 Int Centre For Genetic Engineering And Biotechnology Proteins with cardioprotective activity

Also Published As

Publication number Publication date
CN120518738A (zh) 2025-08-22
JP2025107171A (ja) 2025-07-17
LT3962534T (lt) 2024-05-27
CN113795504B (zh) 2025-05-06
EP3962534A1 (en) 2022-03-09
MX2021013298A (es) 2021-12-10
EP4389211A2 (en) 2024-06-26
US20250057982A1 (en) 2025-02-20
SG11202111267WA (en) 2021-11-29
WO2020221906A1 (en) 2020-11-05
JP2022530168A (ja) 2022-06-27
RS65469B1 (sr) 2024-05-31
DK3962534T3 (da) 2024-04-15
AU2020267029A1 (en) 2021-12-23
US20220193260A1 (en) 2022-06-23
ES2975422T3 (es) 2024-07-05
ZA202309540B (en) 2025-12-17
SI3962534T1 (sl) 2024-08-30
EP4389211A3 (en) 2024-08-28
US12121594B2 (en) 2024-10-22
PT3962534T (pt) 2024-04-03
US12569574B2 (en) 2026-03-10
JP7707075B2 (ja) 2025-07-14
EP3962534B1 (en) 2024-02-21
GB201906052D0 (en) 2019-06-12
HRP20240441T1 (hr) 2024-06-21
IL287525A (en) 2021-12-01
CN113795504A (zh) 2021-12-14
CA3137662A1 (en) 2020-11-05
US20220387625A1 (en) 2022-12-08
HUE066324T2 (hu) 2024-07-28
SMT202400151T1 (it) 2024-05-14
MX2026002607A (es) 2026-04-01
ZA202107778B (en) 2024-02-28
BR112021021626A2 (pt) 2021-12-21
KR20260099232A (ko) 2026-06-26
PL3962534T3 (pl) 2024-06-10
KR20220027829A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
JP2020508685A5 (enExample)
HRP20240441T1 (hr) Proteini s kardioprotektivnim djelovanjem
Kubota et al. The eighth Cct gene, Cctq, encoding the theta subunit of the cytosolic chaperonin containing TCP-1
JP2025184979A5 (enExample)
JP2018520997A5 (enExample)
CN105061604B (zh) sDR5‑Fc融合蛋白突变体及其应用
JP2022513308A5 (enExample)
RU2017143580A (ru) Улучшенные последовательности уриказы и способы лечения
JP2025107171A5 (enExample)
RU2015137851A (ru) Субъединичная вакцина против mycoplasma spp.
AR123788A1 (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
JP2024503091A5 (enExample)
JP2023549357A5 (enExample)
JP2022530168A5 (enExample)
FI3833746T3 (fi) Mini-GDE glykogenoosi III:n hoitamiseksi
PE20240647A1 (es) Estrategias de tratamiento del cancer mediante el uso de vectores de arenavirus
CN113980917A (zh) 一种慢病毒溶解缓冲液及其应用
WO2014036524A4 (en) Genetically modified msc and therapeutic methods
JP2023522154A5 (enExample)
CA2343074A1 (en) Akt nucleic acids, polypeptides, and uses thereof
JPWO2020027010A5 (enExample)
RU2021134816A (ru) Белки с кардиопротекторной активностью
RU2024120533A (ru) Белки с кардиопротекторной активностью
CN104650218A (zh) 一种鱼类前胸腺素α及其应用
WO2024220461A3 (en) Aav capsid proteins having mutations in the vp1 region